Information  X 
Enter a valid email address

Vectura Group plc (VEC)

  Print      Mail a friend

Wednesday 29 May, 2019

Vectura Group plc

Vectura Group plc: AGM Trading Update

RNS Number : 3919A
Vectura Group plc
29 May 2019
 

 

 

AGM Trading Update

 

Chippenham, UK - 29 May 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group"), provides a trading update ahead of its Annual General Meeting ("AGM") being held today at 10.30am at the offices of Clifford Chance LLP, 10 Upper Bank Street, London E14 5JJ.

Based on overall trading performance to date in 2019, the Board confirms the outlook remains in line with guidance for the full year.

Vectura's Chief Executive Officer, James Ward-Lilley, said:

"We continue to focus on executing our strategy and build on the strong operational performance we reported in our 2018 Preliminary Results. We were very pleased with the outcome of our US GSK litigation and the recent EU regulatory filing for QVM149 by Novartis. We look forward to additional news flow in H2 2019; including VR315 (US) repeat clinical study read-out and resubmission, possible partnering of VR647 (US) and potential orphan drug designation for our enhanced niche portfolio of assets. Given our strong balance sheet and ongoing cash generation we continue to review our capital allocation policy, including consideration of material shareholder returns, and will provide further updates in due course."

- Ends-

 

For more information, please contact:

Vectura Group plc

 

David Ginivan - VP Corporate Communications

Elizabeth Knowles - VP Investor Relations

 

+44 (0)7471 352 720

+44 (0)7767 160 565

 

 

Consilium Strategic Communications

 

+44 (0)20 3709 5700

Mary-Jane Elliott / Jessica Hodgson / Susan Stuart / David Daley

 

 

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

About Vectura

Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.

 

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Bayer, Chiesi, Almirall, Dynavax and Tianjin KingYork.

 

Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products, and through the development of high-quality generic alternatives to branded therapies.

 

For further information, please visit Vectura's website at www.vectura.com 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TSTLFFILEFITFIA

a d v e r t i s e m e n t